腫瘍アブレーション市場：技術、治療、適応症別-2025-2030年の世界予測

腫瘍アブレーション市場は、2023年に17億8,000万米ドルと評価され、2024年には20億1,000万米ドルに達すると予測され、CAGR 13.85％で成長し、2030年には44億2,000万米ドルになると予測されています。

腫瘍アブレーションは、高周波アブレーション、冷凍アブレーション、マイクロ波アブレーションなどの方法によって、がん組織や腫瘍を破壊するように設計された低侵襲処置を指します。腫瘍アブレーションの必要性は、がんの有病率の増加と、より低侵襲で、費用対効果が高く、患者に優しい治療法の必要性から生じています。その用途は腫瘍学、特に肝臓がん、腎臓がん、肺がん、骨がんなどに及んでおり、手術と緩和ケアの両方の場面で不可欠なものとなっています。最終用途の範囲には、主に病院、外科センター、がん専門クリニックが含まれます。市場成長は、画像誘導システムやアブレーション技術の向上などの技術的進歩、がん症例の増加、外来患者や非侵襲的処置への嗜好の高まりに大きく影響されています。さらに、最新の潜在的機会は、精度を高めるためのAIとロボティクスの統合や、がん罹患率の高い新興市場へのアブレーション技術の拡大にあります。これらの機会を捉えるための推奨事項には、ハイブリッド技術の研究開発への投資や世界の流通網の拡大が含まれます。しかし、新興国市場における認知度の低さ、高い手術費用、潜在的な術後合併症などの制約が市場成長の妨げになる可能性があります。その他の課題としては、厳しい規制要件や、こうした高度な手技を行うための熟練した専門家の必要性などが挙げられます。イノベーションと研究は、機器の小型化の改善や新しいエネルギー方式の探求といった分野で盛んになる可能性があります。さらに、切除後の腫瘍再発の生物学的理解を深める調査は、治療プロトコルの強化につながります。全体として、腫瘍アブレーション市場は急速な技術進歩を特徴とするダイナミックな市場であるが、規制や資源の課題によって制約を受けています。市場の性質上、成長を促進し既存の障壁を克服するためには、イノベーション、患者中心のアプローチ、戦略的パートナーシップに焦点を当てることが求められます。

市場力学：急速に進化する腫瘍アブレーション市場の主要市場インサイトを公開

腫瘍アブレーション市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • がんの有病率の上昇と効果的な治療の必要性
  • 腫瘍摘出のための低侵襲手術へのシフトの増加
  • 高度ながん治療に対する償還政策の改善
• 市場抑制要因
  • 腫瘍アブレーション機器の設計の複雑さ
• 市場機会
  • 世界の腫瘍アブレーション技術の進歩
  • 腫瘍アブレーションに対する政府の好意的な承認
• 市場の課題
  • デバイスの品質と安全性に関する懸念

ポーターのファイブフォース：腫瘍アブレーション市場をナビゲートする戦略ツール

ポーターのファイブフォース（5つの力）は、腫瘍アブレーション市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：腫瘍アブレーション市場における外部からの影響の把握

外部マクロ環境要因は、腫瘍アブレーション市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析腫瘍アブレーション市場における競合情勢の把握

腫瘍アブレーション市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス腫瘍アブレーション市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、腫瘍アブレーション市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨腫瘍アブレーション市場における成功への道筋を描く

腫瘍アブレーション市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がん罹患率の上昇と効果的な治療法の必要性
    • 腫瘍を除去するための低侵襲手術への移行が増加
    • 進行がん治療の償還政策の改善
  • 抑制要因
    • 腫瘍アブレーションデバイス設計の複雑さ
  • 機会
    • 世界中で腫瘍アブレーション技術の進歩
    • 腫瘍アブレーションに対する政府の好意的な承認
  • 課題
    • デバイスの品質と安全性に関する懸念
• 市場セグメンテーション分析
  • 治療：低侵襲手術を必要とする患者に対する腹腔鏡下アブレーションの急増
  • 適応症：肺がんの治療に腫瘍アブレーションを使用する調査の増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 腫瘍アブレーション市場：技術別

• 凍結療法
• 高強度焦点式超音波
• 不可逆的電気穿孔アブレーション
• レーザー組織内熱アブレーション
• マイクロ波アブレーション
• 高周波アブレーション

第7章 腫瘍アブレーション市場治療別

• 腹腔鏡下アブレーション
• 経皮アブレーション
• 外科的アブレーション

第8章 腫瘍アブレーション市場適応症別

• 乳がん
• 腎臓がん
• 肝臓がん
• 肺がん
• 前立腺がん

第9章 南北アメリカの腫瘍アブレーション市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の腫瘍アブレーション市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの腫瘍アブレーション市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • メドトロニック、FDA承認のOsteoCool 2.0システムで骨腫瘍治療を向上
  • BioTraceIOが超音波ベースのBioTraceIOでFDAの承認を取得
  • FDAがFrancis Medical, Inc.の水蒸気アブレーション療法のVanquishに画期的治療薬指定を付与
• 戦略分析と提言

企業一覧

• Angiodynamics, Inc.
• Bioventus LLC.
• Boston Scientific Corp.
• BVM Medical Limited
• Chongqing Haifu Medical Technology Co., Ltd.
• CONMED Corporation
• CooperSurgical, Inc.
• Erbe Elektromedizin GmbH
• IceCure Medical Ltd.
• Integra LifeSciences Corporation
• Johnson & Johnson Services, Inc.
• Medtronic PLC
• Mermaid Medical A/S
• Smith & Nephew PLC
• Theraclion S. A.

LIST OF FIGURES

• FIGURE 1. TUMOR ABLATION MARKET RESEARCH PROCESS
• FIGURE 2. TUMOR ABLATION MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL TUMOR ABLATION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL TUMOR ABLATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL TUMOR ABLATION MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL TUMOR ABLATION MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES TUMOR ABLATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES TUMOR ABLATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. TUMOR ABLATION MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. TUMOR ABLATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. TUMOR ABLATION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL TUMOR ABLATION MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL TUMOR ABLATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. TUMOR ABLATION MARKET DYNAMICS
• TABLE 7. GLOBAL TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL TUMOR ABLATION MARKET SIZE, BY CRYOABLATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL TUMOR ABLATION MARKET SIZE, BY HIGH-INTENSITY FOCUSED ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL TUMOR ABLATION MARKET SIZE, BY IRREVERSIBLE ELECTROPORATION ABLATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL TUMOR ABLATION MARKET SIZE, BY LASER INTERSTITIAL THERMAL ABLATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL TUMOR ABLATION MARKET SIZE, BY MICROWAVE ABLATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL TUMOR ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL TUMOR ABLATION MARKET SIZE, BY LAPAROSCOPIC ABLATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL TUMOR ABLATION MARKET SIZE, BY PERCUTANEOUS ABLATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL TUMOR ABLATION MARKET SIZE, BY SURGICAL ABLATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL TUMOR ABLATION MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL TUMOR ABLATION MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL TUMOR ABLATION MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL TUMOR ABLATION MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL TUMOR ABLATION MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 34. CANADA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 35. CANADA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 36. CANADA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES TUMOR ABLATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 49. AUSTRALIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 50. AUSTRALIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. CHINA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 52. CHINA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 53. CHINA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. INDIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 55. INDIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 56. INDIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 58. INDONESIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 59. INDONESIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 61. JAPAN TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 62. JAPAN TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 64. MALAYSIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 65. MALAYSIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 67. PHILIPPINES TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 68. PHILIPPINES TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 70. SINGAPORE TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 71. SINGAPORE TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 73. SOUTH KOREA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 74. SOUTH KOREA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 76. TAIWAN TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 77. TAIWAN TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 79. THAILAND TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 80. THAILAND TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 82. VIETNAM TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 83. VIETNAM TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. EUROPE, MIDDLE EAST & AFRICA TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 89. DENMARK TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 90. DENMARK TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 92. EGYPT TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 93. EGYPT TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 95. FINLAND TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 96. FINLAND TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 98. FRANCE TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 99. FRANCE TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 101. GERMANY TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 102. GERMANY TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 104. ISRAEL TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 105. ISRAEL TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. ITALY TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 107. ITALY TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 108. ITALY TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 110. NETHERLANDS TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 111. NETHERLANDS TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 113. NIGERIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 114. NIGERIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 116. NORWAY TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 117. NORWAY TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 118. POLAND TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 119. POLAND TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 120. POLAND TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. QATAR TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 122. QATAR TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 123. QATAR TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 125. RUSSIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 126. RUSSIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 128. SAUDI ARABIA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 129. SAUDI ARABIA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH AFRICA TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH AFRICA TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 134. SPAIN TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 135. SPAIN TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 137. SWEDEN TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 138. SWEDEN TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 140. SWITZERLAND TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 141. SWITZERLAND TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 143. TURKEY TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 144. TURKEY TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 146. UNITED ARAB EMIRATES TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 147. UNITED ARAB EMIRATES TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 149. UNITED KINGDOM TUMOR ABLATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 150. UNITED KINGDOM TUMOR ABLATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 151. TUMOR ABLATION MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 152. TUMOR ABLATION MARKET, FPNV POSITIONING MATRIX, 2023

The Tumor Ablation Market was valued at USD 1.78 billion in 2023, expected to reach USD 2.01 billion in 2024, and is projected to grow at a CAGR of 13.85%, to USD 4.42 billion by 2030.

Tumor ablation refers to minimally invasive procedures designed to destroy cancerous tissue or tumors through methods such as radiofrequency ablation, cryoablation, and microwave ablation. The necessity of tumor ablation arises from the growing prevalence of cancer and the need for less invasive, cost-effective, and patient-friendly treatment options. Its application spans oncology, particularly for liver, kidney, lung, and bone cancers, making it essential in both operational and palliative care settings. The end-use scope primarily includes hospitals, surgical centers, and specialized cancer clinics. Market growth is significantly influenced by technological advancements such as image-guidance systems and improved ablation techniques, rising cancer cases, and an increasing preference for outpatient and non-invasive procedures. Additionally, the latest potential opportunities lie in the integration of AI and robotics for precision, as well as the expansion of ablation technologies into emerging markets with high cancer rates. A recommendation to seize these opportunities includes investing in R&D for hybrid technologies and expanding distribution networks globally. However, limitations such as the lack of awareness in developing regions, high procedural costs, and potential postoperative complications could hamper market growth. Other challenging factors include stringent regulatory requirements and the need for skilled professionals to perform these advanced procedures. Innovation and research could thrive in areas like improving device miniaturization and exploring novel energy modalities. Furthermore, research into better understanding the biology of tumor recurrence post-ablation can lead to enhanced treatment protocols. Overall, the tumor ablation market is dynamic, characterized by rapid technological advancement, yet constrained by regulatory and resource challenges. The nature of the market demands a focus on innovation, patient-centric approaches, and strategic partnerships to drive growth and overcome existing barriers.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Tumor Ablation Market

The Tumor Ablation Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of cancer and need for effective treatments
  • Increasing shift to minimally invasive surgeries to remove tumors
  • Improvements in reimbursement policies for advanced cancer treatments
• Market Restraints
  • Complexity of designing tumor ablation devices
• Market Opportunities
  • Advancements in tumor ablation technologies worldwide
  • Favorable government approvals for tumor ablation
• Market Challenges
  • Concerns associated with quality and safety of the device

Porter's Five Forces: A Strategic Tool for Navigating the Tumor Ablation Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Tumor Ablation Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Tumor Ablation Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Tumor Ablation Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Tumor Ablation Market

A detailed market share analysis in the Tumor Ablation Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Tumor Ablation Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Tumor Ablation Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Tumor Ablation Market

A strategic analysis of the Tumor Ablation Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Tumor Ablation Market, highlighting leading vendors and their innovative profiles. These include Angiodynamics, Inc., Bioventus LLC., Boston Scientific Corp., BVM Medical Limited, Chongqing Haifu Medical Technology Co., Ltd., CONMED Corporation, CooperSurgical, Inc., Erbe Elektromedizin GmbH, IceCure Medical Ltd., Integra LifeSciences Corporation, Johnson & Johnson Services, Inc., Medtronic PLC, Mermaid Medical A / S, Smith & Nephew PLC, and Theraclion S. A..

Market Segmentation & Coverage

This research report categorizes the Tumor Ablation Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across Cryoablation, High-Intensity Focused Ultrasound, Irreversible Electroporation Ablation, Laser Interstitial Thermal Ablation, Microwave Ablation, and Radiofrequency Ablation.
• Based on Treatment, market is studied across Laparoscopic Ablation, Percutaneous Ablation, and Surgical Ablation.
• Based on Indication, market is studied across Breast Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, and Prostate Cancer.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of cancer and need for effective treatments
    • 5.1.1.2. Increasing shift to minimally invasive surgeries to remove tumors
    • 5.1.1.3. Improvements in reimbursement policies for advanced cancer treatments
  • 5.1.2. Restraints
    • 5.1.2.1. Complexity of designing tumor ablation devices
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in tumor ablation technologies worldwide
    • 5.1.3.2. Favorable government approvals for tumor ablation
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with quality and safety of the device
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment: Exponential use of laparoscopic ablation for patients requiring minimally invasive surgery
  • 5.2.2. Indication: Increasing research in using tumor ablation for treating lung cancer
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Tumor Ablation Market, by Technology

• 6.1. Introduction
• 6.2. Cryoablation
• 6.3. High-Intensity Focused Ultrasound
• 6.4. Irreversible Electroporation Ablation
• 6.5. Laser Interstitial Thermal Ablation
• 6.6. Microwave Ablation
• 6.7. Radiofrequency Ablation

7. Tumor Ablation Market, by Treatment

• 7.1. Introduction
• 7.2. Laparoscopic Ablation
• 7.3. Percutaneous Ablation
• 7.4. Surgical Ablation

8. Tumor Ablation Market, by Indication

• 8.1. Introduction
• 8.2. Breast Cancer
• 8.3. Kidney Cancer
• 8.4. Liver Cancer
• 8.5. Lung Cancer
• 8.6. Prostate Cancer

9. Americas Tumor Ablation Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Tumor Ablation Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Tumor Ablation Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Medtronic Elevates Bone Tumor Treatment with FDA-Approved OsteoCool 2.0 System
  • 12.3.2. BioTraceIO receives FDA Approval for Ultrasound-Based BioTraceIO
  • 12.3.3. FDA Grants Breakthrough Designation to Vanquish Water Vapor Ablation Therapy by Francis Medical, Inc.
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Angiodynamics, Inc.
• 2. Bioventus LLC.
• 3. Boston Scientific Corp.
• 4. BVM Medical Limited
• 5. Chongqing Haifu Medical Technology Co., Ltd.
• 6. CONMED Corporation
• 7. CooperSurgical, Inc.
• 8. Erbe Elektromedizin GmbH
• 9. IceCure Medical Ltd.
• 10. Integra LifeSciences Corporation
• 11. Johnson & Johnson Services, Inc.
• 12. Medtronic PLC
• 13. Mermaid Medical A / S
• 14. Smith & Nephew PLC
• 15. Theraclion S. A.